Cosela (Trilaciclib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending
Cosela (Trilaciclib Dihydrochloride) by Pharmacosmos As: FDA Orange Book core substance LOE 2040-11-13, 0 AB generics, $4.3M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pharmacosmos As |
| FDA Application & Pathway | N214200 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-11-13 |
| Last Listed Patent or Exclusivity Date | 2040-11-13 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $4.3M |
| 2024 Medicare Part D Spend | $99K |
| 2024 Medicaid Spend | $4.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 16.6% 2-yr change) |